mProX™ Human AKT2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1024	Magic™ Human AKT2 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

AKT2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Diabetes Research

Related Diseases

Hypoinsulinemic Hypoglycemia With Hemihypertrophy and Type 2 Diabetes Mellitus. Among its related pathways are Hepatocyte growth factor receptor signaling and PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Gene ID

208

UniProt ID

P31751

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

An enzyme called AKT2, or RAC-beta serine/threonine-protein kinase, is encoded by the AKT2 gene in humans. As a component of the insulin signal transduction pathway, it affects metabolite storage. This gene is a suspected oncogene that codes for a protein with SH2-like (Src homology 2-like) domains that is a member of the AKT subfamily of serine/threonine kinases. A generic protein kinase that can phosphorylate a number of well-known proteins is the protein that is encoded. As a component of the insulin signal transduction system, AKT2 plays crucial roles in regulating glucose transport, glycogenesis, and gluconeogenesis. The customized AKT2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat James

A good AKT2 cell line. The company obtains a wide range of membrane protein products which are very reliable. Aug 10 2023

chat Verified Customer

chat Mary

I think this is a quality AKT2 cell line for drug discovery. Apr 13 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Akt2 expression and outcome of patients with advanced pancreatic cancer (PC) treated with erlotinib.

In individuals with advanced PC, hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) staining for Akt2. Using H&E and IHC staining, deparaffinized slices of endoscopically biopsied tumors were examined.

Ref: Banno, Eri, et al. "Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib." International journal of oncology 50.6 (2017): 2049-2058.

Pubmed: 28440469

DOI: 10.3892/ijo.2017.3961

Research Highlights

Different stages of breast cancer progression are associated with distinct roles for AKT isoforms. Specifically, AKT1 is implicated in the growth of the tumor locally, whereas AKT2 is engaged in the spread of the tumor distantly. As a result, AKT2 has a lower prognostic value and is therefore a valuable target for therapy.
Riggio, Marina, et al. "AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins." Scientific reports 7.1 (2017): 44244.
Pubmed: 28287129 DOI: 10.1038/srep44244

All things considered, the results show that ATM- and p53-dependent pro-survival autophagy is triggered by DSBs and is inhibited by AKT2 signaling.
Seiwert, Nina, et al. "AKT2 suppresses pro-survival autophagy triggered by DNA double-strand breaks in colorectal cancer cells." Cell death & disease 8.8 (2017): e3019-e3019.
Pubmed: 28837154 DOI: 10.1038/cddis.2017.418